Development & Aid, Global, Global Geopolitics, Headlines, Health, North America

HEALTH: Drug-Resistant TB a Global Threat

Jim Lobe

WASHINGTON, Oct 22 1997 (IPS) - Drug-resistant tuberculosis (MDR-TB) is now a global threat, having already established itself in all five continents, and a cure remains far beyond the health budgets of most countries, according to the World Health Organisation (WHO) and U.S. health agencies.

Based on testing in 35 countries around the world, a 227-page WHO report, ‘Anti-Tuberculosis Drug Resistance in the World’, has discovered that roughly two percent of all TB cases are MDR-TB, but that one-third of all countries in its survey suffer incident rates of two percent or higher.

It also identifies seven “hot zones” in which MDR-TB cases are so prevalent that the number of patients threaten to overwhelm local and regional health systems. These areas include India, Russia, Latvia, Estonia, the Dominican Republic, Argentina and Cote d’Ivoire.

“As the incidence of MDR-TB begins to grow within the hot zones, it will not be a problem for the people of India or Russia,” says Dr. Michael Iseman, a top U.S. TB specialist. “It will be a problem for the world…This is a potential epidemiological nightmare.”

Amid increasing indications of a resurgence in TB, even in developed countries like the United States, and the emergence of MDR-TB, the WHO declared a “global health emergency” in 1993, the first time such an emergency had ever been declared by the Geneva-based agency.

But Arata Kochi, director of WHO’s Global TB Programme, says that national governments failed to mobilise the resources required to deal with the threat. “Today, I am here to tell you that things are even worse than we thought,” he said, adding, “as a result, we are facing the spectre of incurable tuberculosis,” he told reporters Wednesday.

About two billion people are infected with the TB bacillus although only about 10 percent actually contract the disease during their lifetime. Each year, between six and eight million new cases are reported, while between two and three million people die from to the disease, many of them AIDS victims, according to WHO estimates. TB is transmitted through airborne bacteria and, when active, destroys the lungs.

According to the new report, about 98 percent of the cases are “ordinary” TB, which can be cured at relatively little cost. The remaining cases, however, are MDR-TB, or multidrug-resistant TB, bacilli which resist the major two drugs used to fight TB, isoniazid and rifampicin.

“Today, in most of the world, MDR-TB is a virtual death sentence,” says Iseman, who added that in the United States, treatment of MDR-TB, which still often falls short of a cure, costs 100,000-250,000 dollars. “That represents perhaps the entire TB budget for some countries,” he noted.

Modern medicine developed a cure for tuberculosis, for centuries one of the world’s most dreaded diseases, only after World War II. Doctors found that an inexpensive combination of four antibiotics, administered to the patient over six to eight months was sufficient to cure the illness.

As the decades went by, however, health systems, under increasing pressure to cut their budgets, became complacent about TB, until the late 1980s when the disease began a resurgence, even in industrialised countries.

In the United States, for example, the number of estimated deaths caused by TB grew from about 1.5 million in 1950 to three million in 1995, although much of the increase was due to the rise of AIDS. At the same time, through misapplication of the medications or partial treatments, the TB bacillus evolved strains that became resistant to one or more of the drugs used in these treatments. “Failure to ensure that TB patients take all of their medicines and that patients are fully cured is the underlying cause of both the TB epidemic and of drug-resistant TB,” notes Kochi.

Determining how widespread MDR-TB had become was the purpose of the study released here Wednesday.

“It is not good news,” says Iseman. “This study shows definitively, and for the first time, what we most feared, but could not previously prove – our world again faces the spectre of incurable tuberculosis.”

If one-third of the countries surveyed are experiencing MDR-TB levels at between two and 14 percent of all new TB cases, according to Iseman, “it is likely that there are already many countries with thousands of MDR-TB cases. When you consider that a contagious patient will infect between 20 and 20 people each year in their household, school, workplace, community – these findings are frightening,” he said.

“Because drug-resistant TB is every bit as contagious as the regular TB bacteria,” Kochi says, “the implications for the health of the world if the tide of MDR-TB is not reversed are staggering.”

With treatment of MDR-TB beyond the means of most people afflicted with the disease, WHO is putting most of its efforts into its four-year-old campaign to wipe out ordinary TB.

It has been touting for international use a regimen called Directly Observed Treatment Short-Course, or DOTS. The cure, which costs as little as 15 dollars in the Third World, requires intensive surveillance of patients to ensure that they complete the treatment successfully. It has produced cure rates of 85 percent or more.

“Our emphasis is to stop this disease from spreading,” says Iseman. To do that, the strategy is to dry up the pool of ordinary TB cases which could mutate into MDR-TB. Richard Bumgarner, Kochi’s deputy, estimated the cost of a comprehensive programme “to turn the tide in the anti-TB campaign at as much as 100 million dollars, or almost ten times what WHO currently spends.

One problem faced by developing countries is the lack of health systems that permit them to even identify MRD-TB when it occurs, let alone to treat such cases, according to Paul Nunn, one of the report’s authors.

As for discovering and making available a cure for MDR-TB, “prospects are rather bleak,” Isenman warns.

With the minimum costs of bringing new drugs to market estimated at about 400 million dollars, pharmaceutical companies will not invest their capital in such an effort unless they are likely to realise a return. But TB, like malaria and other resurgent diseases, generally strikes people who can least afford expensive treatment.

 
Republish | | Print |

Related Tags